Biocon Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Biocon Ltd is ₹ 426.15 as of 18 May 15:30 . The P/E Ratio of Biocon Ltd changed from 66.3 on March 2021 to 40.4 on March 2025 . This represents a CAGR of -9.43% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Biocon Ltd changed from ₹ 49056 crore on March 2021 to ₹ 40964 crore on March 2025 . This represents a CAGR of -3.54% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Biocon Ltd for the Mar '26 is ₹ 4569 crore as compare to the Dec '25 revenue of ₹ 4290 crore. This represent the growth of 6.5% The revenue of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 2484 crore as compare to the Dec '25 revenue of ₹ 2365 crore. This represent the growth of 5.02% The ebitda of Biocon Ltd for the Mar '26 is ₹ 992.4 crore as compare to the Dec '25 ebitda of ₹ 657.4 crore. This represent the growth of 50.96% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '26 is ₹ 493.84 crore as compare to the Dec '25 ebitda of ₹ 456.45 crore. This represent the growth of 8.19% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ 198.6 crore over 8 quarters. This represents a CAGR of -52.00% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 243.74 crore over 8 quarters. This represents a CAGR of 26.39% The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 years .

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

FAQs for the comparison of Biocon Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Biocon Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Biocon Ltd is 69,074 Cr while Market cap of Emcure Pharmaceuticals Ltd is 31,951 Cr

What are the key factors driving the stock performance of Biocon Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Biocon Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Emcure Pharmaceuticals Ltd?

As of May 18, 2026, the Biocon Ltd stock price is INR ₹426.15. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1685.3.

How do dividend payouts of Biocon Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Biocon Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.